What's Happening?
Probably Genetic, an AI platform dedicated to the research, diagnosis, and treatment of genetic diseases, has successfully raised $12 million in Series A funding. This investment round was led by Threshold, with additional participation from Y Combinator
and existing investors, bringing the company's total funding to $14 million. The capital will be utilized to expand the core business, facilitate hiring, and enable the company's entry into the drug discovery sector. Probably Genetic's primary offering is a physician-ordered genetic test for patients with undiagnosed rare diseases, who often endure a diagnostic journey averaging seven years. The company offers two pathways for testing: free testing through pharmaceutical partnerships for specific conditions and insurance-billed testing. Probably Genetic's AI platform processes self-reported symptoms, medical records, and biological data to generate phenotypic data, which is intended to train AI models for precision medicine. To date, the platform has amassed data from 130,000 patients. In August, the company received up to $10 million from ARPA-H, an agency within the Department of Health & Human Services, to participate in its Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID) program, leveraging its dataset for patient identification and drug discovery.
Why It's Important?
This funding and the expansion of Probably Genetic's operations hold significant implications for the healthcare industry, particularly in the realm of rare diseases. The ability to accelerate the diagnosis of rare genetic conditions, which often take years to identify, can dramatically improve patient outcomes and quality of life. By leveraging AI and a growing dataset, the company aims to shorten this diagnostic odyssey, reducing the emotional and financial burden on patients and their families. Furthermore, the company's foray into drug discovery, supported by its unique dataset linking genes to clinical outcomes, could revolutionize the development of new therapies. Drugs backed by human genetic evidence are statistically more likely to succeed, making Probably Genetic's approach a potential game-changer for pharmaceutical companies seeking to identify promising drug targets. The involvement of ARPA-H also underscores the U.S. government's commitment to fostering innovation in healthcare and addressing unmet medical needs, particularly for rare diseases that often receive less research funding due to smaller patient populations. This initiative could lead to a more personalized and effective approach to medicine, moving towards a future where preventive therapeutics based on genetic testing are more accessible.
What's Next?
Probably Genetic plans to use the newly secured funding to scale its operations, including expanding its team and enhancing its AI platform. A key development on the horizon is the company's intention to expand beyond saliva samples for genetic testing to include proteomic testing, which requires blood draws, in 2027. This proteomic data is considered crucial for drug discovery and will be funded by pharmaceutical partners rather than patients or insurance. The company will continue to collaborate with its pharmaceutical partners, such as UCB, Biogen, and Ultragenyx, to identify patients for clinical trials and to support the development of new therapies. The ongoing participation in ARPA-H's RAPID program will further solidify its role in leveraging AI and machine learning for precision diagnostics in rare diseases. As the dataset grows and AI models become more sophisticated, the company aims to further reduce diagnostic delays and contribute to the discovery of novel drug targets. The long-term vision includes the potential for personalized preventive therapeutics based on individual genetic profiles, even before symptoms manifest.
Beyond the Headlines
The work of Probably Genetic extends beyond immediate diagnostic and therapeutic advancements, touching upon profound ethical, societal, and technological implications. The collection and utilization of vast amounts of patient genetic and phenotypic data raise important questions about data privacy, security, and equitable access to advanced medical technologies. As AI models become more central to diagnosis and drug discovery, the ethical considerations surrounding algorithmic bias and the potential for misinterpretation of complex genetic information will become increasingly critical. The promise of personalized medicine, while offering immense benefits, also brings challenges related to healthcare disparities, as access to such advanced testing and treatments may not be uniform across all socioeconomic groups. Furthermore, the shift towards preventive therapeutics based on genetic predispositions could redefine our understanding of health and illness, potentially leading to earlier interventions but also raising questions about the psychological impact of knowing future health risks. This development also highlights the growing convergence of artificial intelligence, genomics, and pharmaceutical research, signaling a transformative era in medicine where data-driven insights are at the forefront of combating complex diseases.
